Kombiglyze Xr
Utilized to manage type 2 diabetes to support glycaemic control.
Strengths: 5/500 · 5/1000mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Kombiglyze
- Therapeutic class
Dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination
- Pharmacological class
Biguanide; DPP-4 inhibitor
- Contraindications
diabetic ketoacidosis; renal impairment; hypersensitivity
- Minor side effects
nausea; diarrhoea; gastrointestinal distress
- Moderate side effects
urinary tract infection; headache
- Dosage forms
Prolonged-release tablet
- Administration route
Oral use
- Patient summary
Utilized to manage type 2 diabetes to support glycaemic control.
- Prescription status
POM
- Manufacturer
AstraZeneca
- Onset Time
1–2 weeks
- Duration
Ongoing
- Storage instructions
Store below 25°C.
- Drug interactions
Alcohol; Cimetidine
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Use is not recommended. Breastfeeding: Not recommended.
Precautions and warnings
risk of lactic acidosis; monitor renal function; watch for symptoms of pancreatitis
Serious side effects
lactic acidosis — requires immediate medical attention; pancreatitis — requires immediate medical attention
Mechanism of action
Combines a DPP-4 inhibitor to increase insulin release and a biguanide to decrease hepatic glucose production and improve insulin sensitivity.
Kombiglyze Xr
Utilized to manage type 2 diabetes to support glycaemic control.
Editorial Notes
- Active ingredient(s): Saxagliptin, Metformin
- Listed indication(s): Type 2 Diabetes Mellitus
Usually available as
- 28 tablets - 5/500 mg1478-5-500-mg-17777
- 28 tablets - 5/1000 mg1478-5-1000-mg-17771